Literature DB >> 8668850

Respiratory syncytial virus and parainfluenza virus infections in the immunocompromised host.

C H Wendt1, M I Hertz.   

Abstract

Respiratory syncytial virus (RSV) and parainfluenza virus (PIV) are common causes of respiratory infections in immunocompetent children under the age of 6 years. These viruses belong to a family of enveloped single-stranded RNA viruses, the paramyxoviruses. The clinical manifestations in the normal host range from mild illness to severe croup, bronchiolitis, and pneumonia. After the age of 6 years, reinfections occur, but are characterized by diminishing frequency and severity. In contrast to the normal adult host, severe lower respiratory tract infection can occur in immunocompromised adults as well as children, with significant morbidity and mortality. Similar to the normal host, infection with RSV occurs in epidemics in the winter and spring, while PIV occurs throughout the year. Immunocompromised hosts often have upper respiratory tract symptoms similar to those experienced by normal hosts, as well as a higher incidence of lower respiratory tract symptoms and sinusitis. Lower respiratory tract infection can lead to respiratory failure and death, especially in bone marrow transplant recipients. The diagnosis of RSV and PIV depends on the analysis of specimens obtained from the respiratory tract. Rapid diagnostic tests are readily available for RSV and are less widely used for some of the PIV serotypes. Primary cultures are used for both viruses, but take several days to yield a positive result. Ribavirin, a broad-spectrum antiviral agent, is effective against RSV and PIV in vitro. Clinical trials have shown ribavirin to be of benefit in treating infants infected with RSV. However, clinical trials in immunocompromised patients infected with RSV or PIV have not been carried out. Since infection with RSV and PIV can be severe and life-threatening and treatment with ribavirin is relatively benign, it seems warranted to treat immunocompromised patients infected with RSV or PIV with ribavirin until otherwise proven unwarranted.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8668850

Source DB:  PubMed          Journal:  Semin Respir Infect        ISSN: 0882-0546


  27 in total

1.  Near patient testing for respiratory syncytial virus in paediatric accident and emergency: prospective pilot study.

Authors:  A Mackenzie; N Hallam; E Mitchell; T Beattie
Journal:  BMJ       Date:  1999-07-31

2.  SimulFluor respiratory screen for rapid detection of multiple respiratory viruses in clinical specimens by immunofluorescence staining.

Authors:  M L Landry; D Ferguson
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

3.  Oral ribavirin therapy for lower respiratory tract infection of respiratory syncytial virus complicating bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation.

Authors:  Takehiko Mori; Yukinori Nakamura; Jun Kato; Akiko Yamane; Yoshinobu Aisa; Kei Takeshita; Shinichiro Okamoto
Journal:  Int J Hematol       Date:  2011-01-05       Impact factor: 2.490

4.  The viral transcription group determines the HLA class I cellular immune response against human respiratory syncytial virus.

Authors:  Carolina Johnstone; Elena Lorente; Alejandro Barriga; Eilon Barnea; Susana Infantes; François A Lemonnier; Chella S David; Arie Admon; Daniel López
Journal:  Mol Cell Proteomics       Date:  2015-01-29       Impact factor: 5.911

5.  Respiratory disease due to parainfluenza virus in adult leukemia patients.

Authors:  J A Marcolini; S Malik; D Suki; E Whimbey; G P Bodey
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-02-18       Impact factor: 3.267

6.  Simultaneous detection and identification of human parainfluenza viruses 1, 2, and 3 from clinical samples by multiplex PCR.

Authors:  J E Echevarría; D D Erdman; E M Swierkosz; B P Holloway; L J Anderson
Journal:  J Clin Microbiol       Date:  1998-05       Impact factor: 5.948

7.  Epidemiological features of parainfluenza virus infections: laboratory surveillance in England and Wales, 1975-1997.

Authors:  H Laurichesse; D Dedman; J M Watson; M C Zambon
Journal:  Eur J Epidemiol       Date:  1999-05       Impact factor: 8.082

8.  Antiviral activity of lovastatin against respiratory syncytial virus in vivo and in vitro.

Authors:  T L Gower; B S Graham
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

9.  Multiple, non-conserved, internal viral ligands naturally presented by HLA-B27 in human respiratory syncytial virus-infected cells.

Authors:  Susana Infantes; Elena Lorente; Eilon Barnea; Ilan Beer; Juan José Cragnolini; Ruth García; Fátima Lasala; Mercedes Jiménez; Arie Admon; Daniel López
Journal:  Mol Cell Proteomics       Date:  2010-01-15       Impact factor: 5.911

10.  Respiratory syncytial virus infects and abortively replicates in the lungs in spite of preexisting immunity.

Authors:  Marina S Boukhvalova; Gregory A Prince; Jorge C G Blanco
Journal:  J Virol       Date:  2007-06-27       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.